
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. showcases a strong financial outlook, bolstered by a projected top-line guidance of $735 million to $750 million for 2025, reflecting a substantial $155 million increase attributed to the promising growth potential of Jornay PM, despite initial skepticism in the ADHD market. The company demonstrates robust financial management and confidence, evidenced by a $60 million stock repurchase in 2024 and an additional $90 million authorized, highlighting management's belief in the company’s growth trajectory. Furthermore, the firm boasts an impressive near 60% EBITDA margin while maintaining a healthy cash flow exceeding $300 million annually, positioning it favorably for future investments and strategic expansion.
Bears say
Collegium Pharmaceutical Inc. faces significant challenges that contribute to a negative outlook for its stock, despite being perceived as undervalued with a 4.2x EV/EBITDA ratio based on 2025 projections. Key financial metrics indicate risks in commercialization related to potential delays and quality compliance issues that could adversely affect profitability. Additionally, the company's portfolio is under pressure from generic competition in the pain management market, which impacts its market access and reimbursement rates, further limiting its growth prospects compared to peers.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares